Xconomy: Dendreon has only itself to blame for Provenge fiasco

Xconomy's Luke Timmerman takes Dendreon to task for its acknowledged blunder marketing Provenge. Chiding the biotech for overreaching on price, failing to get its marketing ducks in a row ahead of an approval and fumbling its outreach to physicians, Timmerman adds that Dendreon's ($DNDN) failure is limited to a single company, with more experienced players like Vertex (Incivek) and Bristol-Myers Squibb (Yervoy) finding success with their new drugs. Of course, their success also begs the question whether Dendreon had fully explained all the reasons for Provenge's sudden disappointment. And today, on another bad day on Wall Street, Dendreon's battered shared slid another 11 percent. Column

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.